

Supplementary Information

Novel triple mutant of an extremophilic glycosyl hydrolase allows the rapid synthesis of thioglycosides

Lauriane Pillet,^a David Lim,^a Nourah Almulhim,^b Ana I. Benítez-Mateos,^a and Francesca Paradisi ^{*a,b}

^a *Department of Chemistry, Biochemistry, and Pharmaceutical Sciences, University of Bern, Freiestrasse 3, CH-3012 Bern, Switzerland*

^b *School of Chemistry, University of Nottingham, University Park, NG7 2RD, Nottingham, UK*

* *E-mail: francesca.paradisi@unibe.ch*

Table of contents

1. Materials and methods	2
1.1. Reagents	2
1.2. DNA preparation and site-directed mutagenesis	2
Table S1. Primer used to design the 8 <i>HorGH1</i> variants	3
Figure S1: Diagram of the catalytic site and <i>HorGH1</i> variants sequences	4
1.3. <i>HorGH1</i> variants expression, purification and quantification	5
Figure S2: SDS-PAGE after purification of <i>HorGH1</i> variants	6
1.4. Activity assay	7
Figure S3: Calibration curves and determination of ϵ for <i>pNP</i> and <i>pNT</i>	7
1.5. Biotransformations	8
Figure S4: Screening of different reducing agents	8
Figure S5: Conversion for <i>HorGH1</i> variants E166A and <i>HorGH1</i> M299R/E166A	9
Figure S6: Conversion for <i>HorGH1</i> variants E166A/E354G and <i>HorGH1</i> M299R/E166A/E354G	10
Figure S7: Enzyme kinetics	12
Figure S8: $^1\text{H-NMR}$ for the synthesis of <i>pNT-Glc</i> chemically and enzymatically	13
Figure S9: Activity of the different <i>HorGH1</i> variants towards <i>pNP-Glc</i> and <i>pNT-Glc</i>	14
Figure S10: Thioglycoside products formed with <i>HorGH1</i> M299R/E166A/E354G	15
Table S2: Confirmation of thioglycoside synthesis by HRMS	16
Figure S11: Screening of the effect of pH on thioglycoside conversion	17
Figure S12: Calibration curve of the thioglycosides (HPLC)	18
Figure S13: Representative chromatogram of the bio-synthesis of <i>pNT</i>	19
Figure S14: $^1\text{H-NMR}$ of the reaction of $\alpha\text{-D-glucopyranosyl fluoride}$ with 2-mercaptopyridine	21
1.6. Synthesis of the thioglycoside standards	22
Scheme S1: Synthesis of aryl thioglycosides	23
2. Spectral data	27
3. Supplementary References	33

1. Materials and methods

1.1. Reagents

All components required to perform PCR reactions were purchased from New England Biolabs (NEB), except the QuickChange Lightning multi site-directed mutagenesis kit that was purchased from Agilent. Primers were synthesised by the Microsynth company. GeneJET plasmid miniprep kit was purchased from ThermoFisher Scientific. All chemical reagents were acquired from Sigma Aldrich (Merck KGaA, Darmstadt) unless otherwise specified. The HisTrapFF crude[®] column used for protein purification was purchased from Cytiva. 4-nitrophenyl- β -D-glucopyranoside (*p*NP-Glc) used for activity assays was purchased from Carbosynth. All commercial chemicals were used without further purification. *p*-nitrophenyl- β -D-thioglucopyranoside (*p*NP-Glc), phenyl- β -D-glucopyranoside, *p*-toluyl- β -D-glucopyranoside and *p*-bromophenyl- β -D-thioglucopyranoside were synthesised in house according to literature procedure. The synthetic details are indicated in section **1.6: Synthesis of the thioglycoside standards**.

1.2. DNA preparation and site-directed mutagenesis

The different *HorGH1* variants used in this study were produced *via* the traditional quick-change PCR using the Q5[®] high-fidelity DNA polymerase (*HorGH1* E166A, *HorGH1* M299R/E166A), *via* the Q5[®] site-directed mutagenesis kit (*HorGH1* E354G, *HorGH1* M299R/E354G) or *via* the QuickChange Lightning multi site-directed mutagenesis kit (*HorGH1* M299R, *HorGH1* E166A/E354G, *HorGH1* M299R/E166A/E354G). The pET45b plasmid hosting the ds-DNA of *HorGH1* (GeneBank accession number WP_012636460)^{1,2} and the *HorGH1* M299R¹ variants were used as templates in the PCR reactions.


1.2.1. Primers design

Table S1: Sequences of the primer used to design the *HorGH1* variants.

Entry	Primer type	Variants created	Sequence
1	M299R	<i>HorGH1</i> M299R	5'-AATTATTACAGTAGAAGGGTCGTACGCCATAAG-3'
2	E166A forward (F_E166A)	<i>HorGH1</i> E166A, <i>HorGH1</i> M299R E166A	5'-GTGACTCATAACGCACCGTGGGTTGTGG-3'
3	E166A reverse (R_E166A)	<i>HorGH1</i> E166A, <i>HorGH1</i> M299R E166A	3'-CCACAACCCACGGTGC GTTATGAGTCAC-5'
4	E354G forward (F_E354G)	<i>HorGH1</i> E3454G, <i>HorGH1</i> M299R E354G	5'-CTTTGTACATTACTGGTAACGGTGCCGCGTT-3'
5	E354G reverse (R_E354G)	<i>HorGH1</i> E3454G, <i>HorGH1</i> M299R E354G	3'-GCTTGTCGGTGTATTCTTTGTTTACTCTGACC-5'
6	E166A	<i>HorGH1</i> E166A E3454G, <i>HorGH1</i> M299R E166A E3454G	5'-GGGTGACTCATAACGCACCGTGGGTTGTGG- 3'
7	E354G	<i>HorGH1</i> E166A E3454G, <i>HorGH1</i> M299R E166A E3454G	5'-CAAGCCTTTGTACATTACTGGAAACGGTGCCGCGT-3'

Once the PCR reactions were performed, produced DNA was used to transform by heat-shock at 42 °C the appropriate competent cells adapted to each PCR protocol. The GeneJET plasmid miniprep kit from ThermoFisher Scientific was used to extract the DNA for sequencing.

1.2.2. *HorGH1* variants mutations and sequences



C

MAHHHHHHVGTGSNDDDDKSPMAKIIFPEDFIWGAATSSYQIEGAFNEDGKGESIWD RFSHTPGKIENGD TGDIACDHY
 HLYREDIELMKEIGIRSYRFSTSWPRILPEGKGRVNQKGLDFYKRLVDNLLKANIRPMITLYHWDLPQALQDKGGW TNRDT
 AKYFAEYARLMFEEFNGLVDLWVTHNEPWWVAFEGHAFGNHAPGTKDFKTALQVAHLLLSHGMAVDIFREEDLPGEIGI
 TLNLTPAYPAGDSEKDVKAASLLDDYINAWFLSPVFKGSYPEELHHIYEQNLGAFTTQPGDMDIISRDI DFLGINYYSRMVVR
 HKPGDNLFNAEVVKMEDRPSTEMGW EIYPQGLYDILVRVNKEYTDKPLYITENGA AFDDKLTEEGKIHDEKRINYLGDHFK
 QAYKALKDGVPLRGYYVWSLMDNFEWAYGYSKRFLIYVDYENGNRRFLKDSALWYREVIEKGQVEANGYPNWELVYTA
 RLQVDKLA AALES GKETA AAKFERQH MDSSTSA A


D

MAHHHHHHVGTGSNDDDDKSPMAKIIFPEDFIWGAATSSYQIEGAFNEDGKGESIWD RFSHTPGKIENGD TGDIACDHY
 HLYREDIELMKEIGIRSYRFSTSWPRILPEGKGRVNQKGLDFYKRLVDNLLKANIRPMITLYHWDLPQALQDKGGW TNRDT
 AKYFAEYARLMFEEFNGLVDLWVTHNAPWWVAFEGHAFGNHAPGTKDFKTALQVAHLLLSHGMAVDIFREEDLPGEIGI
 TLNLTPAYPAGDSEKDVKAASLLDDYINAWFLSPVFKGSYPEELHHIYEQNLGAFTTQPGDMDIISRDI DFLGINYYSRVVR
 HKPGDNLFNAEVVKMEDRPSTEMGW EIYPQGLYDILVRVNKEYTDKPLYITGN GA AFDDKLTEEGKIHDEKRINYLGDHFK
 QAYKALKDGVPLRGYYVWSLMDNFEWAYGYSKRFLIYVDYENGNRRFLKDSALWYREVIEKGQVEANGYPNWELVYTA
 RLQVDKLA AALES GKETA AAKFERQH MDSSTSA A

Figure S1: Diagram of the catalytic site of **A)** wild type *HorGH1* **B)** *HorGH1* M299R/E166A/E354G variant. Protein sequences of wild type *HorGH1* **(C)** and *HorGH1* M299R/E166A/E354G **(D)**. Wild type E166 and E354 glutamic acid residues are highlighted in blue and M299 methionine residue is highlighted in orange in the wild type *HorGH1*. E166A and E354G mutations of glutamic acid residues in alanine and glycine residues are highlighted in green and violet, respectively, while M229R mutation is highlighted in red in the *HorGH1* M299R/E166A/E354G variant.

1.3. *HorGH1* variants expression, purification and quantification

The pET45b plasmids harboring the genes of the different *HorGH1* variants were transformed into chemically competent *E.coli* BL21(DE3) cells. Then, 1L flasks containing 300 mL of autoinduction media (10 g/L N-Z-amine, 5 g/L yeast extract, 50 mM KH_2PO_4 , 50 mM K_2HPO_4 , 25 mM $(\text{NH}_4)_2\text{SO}_4$) with 100 $\mu\text{g}/\text{mL}$ ampicillin were inoculated with a single colony and incubated at 37 °C and 150 rpm for 24 hours. Cells (3 g) were harvested by centrifugation at 2500-g, 4 °C, 20 min and resuspended in 7.5 mL of loading buffer (50 mM HEPES, 150 mM NaCl, 10 mM imidazole, pH 7.5). The suspension was placed on ice and lysed by sonication at 40 % amplitude for 8 min, with pulses of 5 s ON, 10 s OFF. After centrifugation at 12,100-g, 4 °C, 45 min, the supernatant was filtered with a 0.45 μm filter. *HorGH1* variants were then purified by metal affinity chromatography (IMAC) using an AKTA™ Start. Pure fractions were pooled and dialysed for 20 h at room temperature with dialysis buffer (50 mM HEPES pH 7.5, 150 mM NaCl) with one buffer exchange after 2h. Purification of the enzyme was checked by analysing the different fractions with a 12 % SDS PAGE, by staining with Coomassie blue (**Figure S2**). The concentration of the purified enzymes was estimated by measuring the absorbance at 280 nm in the EPOCH2 (nanodrop Take3 plate) using an extinction coefficient (ϵ) of 106,230 $\text{L}\cdot\text{mol}^{-1}\cdot\text{cm}^{-1}$ (predicted using the ExPASy ProtParam tool^{1,2}) and a molecular weight of 52,003.56 Da.^{1,5} Low protein concentrations (< 1 mg/mL) were determined by Bradford assay by measuring the absorbance at 595 nm of a solution containing 5 μL of protein sample with 250 μL of Bradford reagent. A calibration curve was performed with the BSA protein. Typically, starting from 3 g of wet cell paste, it was possible to obtain 25 mg of pure protein (5 fractions of 5 mg/mL, 83 mg/L of culture).



B

Variant	Expression yield [mg/L _{culture}]
<i>HorGH1</i>	114.5
<i>HorGH1 E166A</i>	81.1
<i>HorGH1 E354G</i>	158.1
<i>HorGH1 E166A E354G</i>	80.7
<i>HorGH1 M299R</i>	34.1
<i>HorGH1 M299R E166A</i>	82.1
<i>HorGH1 M299R E354G</i>	80.1
<i>HorGH1 M299R E166A E354G</i>	96.7

Figure S2: (A) SDS-PAGE after the expression and purification of the different *HorGH1* variants. Line 1: *HorGH1* Line 2: *HorGH1 E166A*. Line 3: *HorGH1 E354G*. Line 4: *HorGH1 E166A E354G*. Line 5: *HorGH1 M299R*. Line 6: *HorGH1 E166A M299R*. Line 7: *HorGH1 E354G M299R*. Line 8: *HorGH1 E166A E354G M299R*. Mw: prestained protein ladder V from Geneaid. All protein samples were loaded in the SDS-PAGE at similar concentration. (B) Expression yields of the different *HorGH1* variants.

1.4. Activity assay


The activity of the *HorGH1* variants were measured in triplicates by monitoring the change in absorbance at 420 nm of *p*-nitrophenol (*p*NP) and *p*-nitrothiophenol (*p*NT). The molar extinction coefficient (ϵ) for the products were determined by obtaining a calibration curve of absorbance as a function of concentration (**Figure S3**) and was calculated according to Equation (1):

$$\epsilon [L \cdot \text{mol}^{-1} \cdot \text{cm}^{-1}] = \frac{A}{l [\text{cm}] \cdot c [\text{mol} \cdot L^{-1}]} \quad (1)$$

With A the absorbance, l the pathlength and c the concentration. Activity assays were conducted in a 96-well plate at a total volume of 300 μL , at 25 $^{\circ}\text{C}$ and for 10 minutes. A typical reaction mixture contained 290 μL of 4-nitrophenyl- β -D-glucopyranoside (*p*NP-Glc, 10 mM) or 4-nitrophenyl- β -D-thioglucopyranoside (*p*NT-Glc, 10 mM, concentration of DMSO controlled at 9 % across the assay) in 50 mM HEPES buffer pH 7.4 and 10 μL of the enzyme with appropriate dilution (approx. 60 $\mu\text{g}/\text{mL}$ final concentration). The specific enzyme activity A_{HorGH1} [U/mg] was calculated according to Equation (2):

$$A_{\text{HorGH1}} \left[\frac{\mu\text{mol}}{\text{min} \cdot \text{mg}} \right] = \frac{S [\Delta A \cdot \text{min}^{-1}]}{\epsilon [L \cdot \text{mol}^{-1} \cdot \text{cm}^{-1}] \cdot l [\text{cm}]} \cdot \frac{V_{\text{tot}} [\mu\text{L}] \cdot DF}{V_{\text{enzyme}} [\mu\text{L}] \cdot c_{\text{enzyme}} \left[\frac{\text{mg}}{\text{mL}} \right]} \cdot \frac{10^6 [\mu\text{mol} \cdot \text{mol}^{-1}]}{10^3 [\text{mL} \cdot L^{-1}]} \quad (2)$$

With S the slope of absorbance as a function of time, ϵ the molar extinction coefficient, l the pathlength, V_{tot} the total volume of the assay (300 μL), V_{enzyme} the volume of enzyme solution added in the assay (10 μL), DF the dilution factor of the enzyme solution and c_{enzyme} the concentration of the enzyme solution.



B

	<i>p</i> -nitrophenol (<i>p</i> NP)	<i>p</i> -nitrothiophenol (<i>p</i> NT)
$\epsilon [L \cdot \text{mol}^{-1} \cdot \text{cm}^{-1}]$	10291.8	7125.5

Figure S3 A) Calibration curve of the absorbance as a function of p-nitrophenol (pNP) and p-nitrothiophenol (pNT) concentration **B)** Determination of the molar extinction coefficient ϵ [$\text{L}\cdot\text{mol}^{-1}\cdot\text{cm}^{-1}$].

1.5. Biotransformations

1.5.1. Screening of the thioglycosidic synthetic capability of the different *HorGH1* variants

Reactions were performed at 25 °C for 24 h in 50 mM bicarbonate buffer pH 9.4 containing 30 % DMSO, 1 mg/mL enzyme, 1 mM sugar donor, 20 mM β -mercaptoethanol (**Figure S4**) and 1, 2, 5 and 10 mM of *p*-nitrothiophenol (*p*NT) in a total reaction volume of 1 mL.

1.5.2. Screening of different reducing agents on enzyme performance






Figure S4: Screening of the effect of tris(2-carboxyethyl)phosphine (TCEP), dithiothreitol (DTT) and β -mercaptoethanol reducing agents on *HorGH1* M299R/E166A/E354G thioglycosides synthetic performance.


1.5.3. *HorGH1* E166A and *HorGH1* M299R/E166A




A Conversion (pNT-Glc) as a function of time for *HorGH1* E166A + pNP-Glc + pNT



B Conversion (pNP) as a function of time for *HorGH1* E166A + pNP-Glc + pNT



C Conversion (pNT-Glc) as a function of time for *HorGH1* E166A/M299R + pNP-Glc + pNT



D Conversion (pNP) as a function of time for *HorGH1* E166A/M299R + pNP-Glc + pNT




Figure S5: Conversion of **A**) 4-nitrophenyl- β -D-thioglucopyranoside (pNT-Glc, thioglycoside) and **B**) *p*-nitrophenol (pNP, leaving group) for reactions with the acid/base mutant E166A and conversion of **C**) 4-nitrophenyl- β -D-thioglucopyranoside (pNT-Glc, thioglycoside) and **D**) *p*-nitrophenol (pNP, leaving group) for reactions with the acid/base mutant M299R/E166A. Reactions were performed at 25 °C in 50 mM HEPES buffer pH 7.4 containing 30 % DMSO in the presence of 0.3 mg/mL enzyme, 1 mM sugar donor, 20 mM β -mercaptoethanol and an excess of pNT in a total reaction volume of 1 mL.

1.5.4. *HorGH1* E166A/E354G and *HorGH1* M299R/E166A/E354G






Figure S6: Conversion of 4-nitrophenyl- β -D-thioglucopyranoside (*p*NT-Glc, thioglycoside) for variants depleted of both catalytic residues. **A)** *HorGH1* E166A/E354G and **B)** *HorGH1* M299R/E166A/E354G. Reactions were performed at 25 °C in 50 mM HEPES buffer pH 7.4 containing 30 % DMSO in the presence of 0.3 mg/mL enzyme, 1 mM sugar donor, 20 mM β -mercaptoethanol and an excess of *p*NT in a total reaction volume of 1 mL.

1.5.5. Enzyme kinetics

Enzyme kinetics towards *p*NT were performed at 25 °C in 50 mM bicarbonate buffer pH 9.4 containing 30 % DMSO in the presence of 0.3 mg/mL enzyme, 1 mM sugar donor, 20 mM β-mercaptoethanol and 0.5 mM, 1 mM, 2 mM, 10 mM or 20 mM *p*NT in a total reaction volume of 1 mL. Enzyme kinetics towards α-D-glucopyranosyl fluoride were performed under the same conditions with 10 mM *p*NT and 0.5 mM, 1 mM, 2 mM, 5 mM, 10 mM or 20 mM α-D-glucopyranosyl fluoride. Reaction mixtures were analysed by HPLC at 15 min, 30 min, 1h, 2h, and 4h, and used to determine the activity [U/mg], which was calculated according to the following equation:

$$A_{HorGH1\ variants} \left[\frac{\mu mol}{min \cdot mL} \right] = \frac{S [mmol \cdot L^{-1} \cdot min^{-1}] \cdot 10^3 [\mu mol \cdot mmol^{-1}]}{c_{enzyme} [mg \cdot mL^{-1}] \cdot 10^3 [L \cdot mL^{-1}]}$$

With S [mM/min] the slope of conversion as a function of time and c_{enzyme} [mg/mL] the enzyme concentration in the biotransformation. K_M and V_{max} were then determined online.³



	<i>HorGH1</i> E166A E354G M299R	<i>HorGH1</i> E166A E354G
$K_{M, pNT}$ [mM]	3.82 ± 1.34	7.46 ± 1.27
$V_{max, pNT}$ [U/mg]	$1.36 \pm 0.17 \cdot 10^{-2}$	$1.28 \pm 0.09 \cdot 10^{-2}$
$K_{M, \alpha-D-glc}$	2.26 ± 0.23	2.12 ± 0.30
$V_{max, \alpha-D-glc}$ [U/mg]	$2.67 \pm 0.08 \cdot 10^{-2}$	$2.36 \pm 0.09 \cdot 10^{-2}$

Figure S7: Enzyme kinetics towards pNT for (A) *HorGH1* M299R/E166A/E354G and (B) *HorGH1* E166A/E354G and towards α -D-glucopyranosyl fluoride for (C) *HorGH1* M299R/E166A/E354G and (D) *HorGH1* E166A/E354G.

1.5.6. Confirmation of thioglycoside synthesis by ^1H NMR

The synthesis of the thioglycoside standards were performed as described in section 1.6. **Synthesis of the thioglycoside standards** and the ^1H NMR spectra of the products were obtained using D_2O as the solvent (Figure S7 A). The enzymatic reaction was performed with the *HorGH1* M299R/E166A/E354G variant as described in section 1.5.1 in 50 mM HEPES buffer pH 7.4 containing 30 % deuterated DMSO with 10 mM of pNT. The water was then removed under reduced pressure, and 700 μL of d_6 -DMSO was added (Figure S7 B). A ^1H NMR spectrum of the mixture was then obtained.




Figure S8: Overlaid ^1H NMR spectra of authentic *p*-nitrophenyl- β -D-thioglucopyranoside (*p*NT-Glc) (A) and the biocatalytic using our triple mutant *HorGH1* M299R/E166A/E354G (B). Chemical shifts for the anomeric and aromatic protons of the product are provided: δ_{H} (300 MHz, d_6 -DMSO) 5.10 (1H, d, $J_{1,2}$ 9.6 Hz, H-1), 7.71 (1H, d, J 9.0 Hz, Ar-H), 8.22 (1H, d, J 9.0 Hz, Ar-H).

1.5.7. Activity of the different *HorGH1* variants with *pNP*-Glc and *pNT*-Glc




Figure S9: Activity of the different *HorGH1* variants towards 4-nitrophenyl- β -D-glucopyranoside (*pNP*-Glc) and 4-nitrophenyl- β -D-thioglucopyranoside (*pNT*-Glc). All variants lacking either the catalytic acid/base or the nucleophilic residues had an activity of <0.01 U/mg towards *pNP*-Glc and no activity towards *pNT*-Glc. Among the mutants, *HorGH1* E166A and *HorGH1* M299R E166A displayed the highest activity (0.01 U/mg towards *pNP*-Glc), however this represents only 0.06 % of the wild type activity.

1.5.8. Screening of the thiols accepted by the *HorGH1* M299R/E166A/E354G variant

Reactions were performed with α -D-glucopyranosyl fluoride as the sugar donor and either *p*-nitrothiophenol, thiophenol, *p*-thiitoluene, and *p*-bromothiophenol as the acceptor. Reactions were performed at 25 °C in 70 % 50 mM bicarbonate buffer pH 9.4 containing 30% DMSO, 1 mg/mL enzyme, 1 mM sugar donor, 20 mM β -mercaptoethanol and 10 mM of *p*NT in a total reaction volume of 1 mL.




Figure S10: Conversion of the thioglycoside products resulting from the screening of thiols accepted by the *HorGH1* M299R/E166A/E354G variant. Reactions were performed at 25 °C in 50 mM bicarbonate buffer pH 9.4 containing 30 % DMSO in the presence of 1 mg/mL enzyme, 1 mM sugar donor and 10 equivalents excess of thiol acceptor in a total reaction volume of 1 mL.

1.5.7. Confirmation of thioglycoside synthesis by HRMS

Thioglycoside product	Formula	Calculated m/z	Obtained m/z
<i>p</i> -nitrophenyl- β -D-thioglucopyranoside (3a)	C ₁₂ H ₁₅ O ₇ NS	(M + H ⁺) 318.0650	(M + H ⁺) 318.0642
		(M + Na ⁺) 340.0467	(M + Na ⁺) 340.0461
phenyl- β -D-thioglucopyranoside (3b)	C ₁₂ H ₁₆ O ₅ S	(M + H ⁺) 273.0800	(M + H ⁺) 273.0791
		(M + Na ⁺) 295.0611	(M + Na ⁺) 295.0611
phenyl- β -D-thioglucopyranoside (3c)	C ₁₃ H ₁₈ O ₅ S	(M + H ⁺) 287.0950	(M + H ⁺) 287.0948
		(M + Na ⁺) 309.0767	(M + Na ⁺) 309.0767
<i>p</i> -bromophenyl- β -D-thioglucopyranoside (3d)	C ₁₂ H ₁₅ BrO ₅ S	(M + H ⁺) 350.9900	(M + H ⁺) 350.9896
		(M + Na ⁺) 372.9718	(M + Na ⁺) 372.9716
pyridinyl- β -D-thioglucopyranoside (3f)	C ₁₁ H ₁₅ O ₅ S	(M + H ⁺) 274.0750	(M + H ⁺) 274.0750
		(M + Na ⁺) 296.0567	(M + Na ⁺) 296.0570

Table S2: Calculated and obtained masses for the enzymatically synthesized thioglycosides

1.5.9. Screening of the effect of pH on thioglycoside conversion




Figure S11: Effect of pH on the thioglycoside product conversion for the *HorGH1* M299R/E166A/E354G variant using 1 mM sugar donor and (A) 10 mM *p*-nitrothiophenol (pNT) (B) 10 mM thiotoluene as the thiol acceptor. Reactions were performed at 25 °C in 50 mM HEPES buffer pH 7.4, 50 mM phosphate buffer pH 8.4 or 50 mM bicarbonate buffer pH 9.4 containing 30 % DMSO.

1.5.10. HPLC analysis

Reactions were monitored by RP-HPLC for products **3a-d**. Conversions were determined based on product formation by HPLC (Dionex, UltiMate 3000 Thermo Fisher, Loughborough, UK) equipped with a C18 column 3.5 μm , 2.1 \AA , 150 mm (Waters, Elstree, UK). 2 μL of sample was injected and submitted to a gradient method of 5:95 to 95:5 [$\text{H}_2\text{O}/\text{ACN}$ containing 0.1 % trifluoroacetic acid (TFA)] over 4 mins with a flow rate of 0.8 mL/min. Samples were detected using a UV detector at 330 nm. Calibration curves of the thioglycoside products (*p*-nitrophenyl- β -D-thioglucofuranoside, phenyl- β -D-thioglucofuranoside, *p*-toluyl- β -D-thioglucofuranoside and *p*-bromophenyl- β -D-thioglucofuranoside) were obtained using synthetic samples (**Figure S12**). 50 μL of reaction mixture was added to 225 μL of acetonitrile and 225 μL of 0.2 % aq. HCl in H_2O . Samples were filtered through 0.45 μM PTFE filter prior to HPLC analysis. Conversions X [%] were calculated from HPLC analyses of the reaction mixture according to Equation (3):

$$X [\%] = \frac{A_{\text{HPLC}} [\text{mAU} \cdot \text{min}]}{\text{Slope}_{\text{cal}} [\text{mAU} \cdot \text{min} \cdot \text{mM}^{-1}] \cdot 1 [\text{mM}]} \quad (3)$$

With A_{HPLC} the peak area corresponding to the thioglycoside product (retention times exactly matched the calibration curve) and $\text{Slope}_{\text{cal}}$ the slope of the calibration curve. Examples of chromatograms can be found in **Figure S13**.




Figure S12: Calibration curves of the different thioglycosides using authentic samples of the product.




Figure S13: HPLC chromatogram of the reaction of α -D-glucopyranosyl fluoride with *p*-nitrothiophenol (*p*NT) at 25°C for 24h in 50 mM bicarbonate buffer pH 9.4 containing 30 % DMSO, 24h, 1 mg/mL enzyme, 1 mM sugar donor, 20 mM β -mercaptoethanol and 10 mM thiol acceptor, to give *p*-nitrophenyl- β -D-thiogluco-pyranoside as product **A**) In the presence of the *HorGH1* M299R/E166A/E354G mutant and **B**) without enzyme. The first peak at $R_t= 4.860$ min corresponds to the thioglycosidic product, the second peak at $R_t= 6.377$ min to the thiol donor and the third peak at $R_t=7.23$ min to the disulfide version of the thiol donor. No product peak is seen in the absence of the enzyme. In the presence of *HorGH1*, *HorGH1* M299R, *HorGH1* E354G and *HorGH1* M299R/E354G, chromatograms looked the same as **Figure S13 B**. Chromatograms with other thiol acceptors followed the same pattern of thioglycosidic product, thiol acceptor, and thiol disulfide as **Figure S13 A**, but with different retention times.

1.5.11. Determination of conversion via ^1H NMR

Conversion of products **3e-f** were determined by ^1H -NMR (Bruker Ascend™ 300 (300 MHz) spectrometer) using the integrals of the anomeric protons of the starting materials and product. Reactions were performed as previously described (section 1.5.7. Screening of the thiols accepted by the *HorGH1* M299R/E166A/E354G variant) but in deuterated solvents and on a 10 mM scale. Bicarbonate buffer 50 mM pH 9.8 and the enzyme (1 mg/mL) were freeze-dried and redissolved in D_2O , while α -D-glucopyranosyl fluoride was directly dissolved in D_2O . The respective thiol acceptor (*p*-aminothiophenol or 2-mercaptopyridine) and β -mercaptoethanol were dissolved in d_6 -DMSO. ^1H NMR spectra were acquired at different time points with 64 scans. Conversion was determined based on the ratio between the integrals of anomeric proton of the product and the sum of the integrals of the anomeric protons of the starting material and product according to the following equation:

$$X [\%] = \frac{A_{thioglycoside}}{A_{thioglycoside} + A_{\alpha - D - glucopyranosyl fluoride}} \quad (4)$$

With $A_{thioglycoside}$ representing the integral of the anomeric proton of the thioglycoside product and $A_{\alpha - D - glucopyranosyl fluoride}$ the integral of the starting material (**Figure S13 B**).





Figure S14: ^1H NMR spectra of the reaction of α -D-glucopyranosyl fluoride with 2-mercaptopyridine over time at 25 °C in 50 mM bicarbonate buffer pH 9.4 in D_2O containing 30 % d_6 -DMSO, 1 mg/mL enzyme, 10 mM sugar donor, 200 mM β -mercaptoethanol and 100 mM thiol acceptor in a total volume of 1 mL (**A**) and integrals of relevant peaks used to determine product conversion after 72h (**B**) No product peak was observed in the absence of the enzyme. Chemical shifts for the anomeric protons of the starting material and product are provided: δ_{H} (300 MHz, d_6 -DMSO) 5.25 (1H, d, $J_{1,2}$ 9.9 Hz, H-1), 5.65-5.83 (1H, dd, J_{1-F} 53.7 Hz, J_{1-2} 2.8 Hz, H-1)


1.6. Synthesis of the thioglycoside standards

Reactions conducted at 0 °C were cooled by means of an ice bath. Solvent was removed under reduced pressure using a Buchi™ rotary evaporator. Reagents were used as supplied without further purification unless otherwise stated. Unless stated, reactions were performed under an atmosphere of nitrogen. Thin Layer Chromatography (t.l.c.) was carried out on Merck Silica Gel 60F254 aluminium-backed plates. Visualisation of the plates was achieved using a UV lamp ($\lambda_{\text{max}} = 254$ or 365 nm). Flash column chromatography was carried out using Silicycle SiliaFlash® P60 silica (230-400 mesh). Proton and carbon nuclear magnetic resonance (δ_{H} , δ_{C}) spectra were recorded on a Bruker Ascend™ 300 (300MHz) spectrometer. All chemical shifts are quoted on the δ -scale in ppm using the residual solvent as an internal standard. ^1H and ^{13}C spectra were assigned using COSY, DEPT, HSQC, and HMBC. High resolution mass spectra were recorded a Bruker FT-ICR mass spectrometer using electrospray ionisation (ESI). M/z values are reported in Daltons.

1.6.1. *p*-Nitrophenyl β -D-glucopyranoside **1**




D-Glucose (1.0 g, 5.55 mmol), Et_3N (6.90 mL, 50.0 mmol), and 4-nitrothiophenol (4.30 g 27.8 mmol) were stirred in $\text{H}_2\text{O}/\text{MeCN}$ (1:1, 10 mL). The mixture was cooled to 0 °C. DMC (2.80 g, 16.7 mmol) was then added portionwise. The mixture was allowed to stir for 2 h, at which time, the mixture was diluted with water (40 mL). The aqueous phase was washed with DCM (2 x 50 mL) and then concentrated *in vacuo*. Purification of the residue by flash column chromatography (DCM/MeOH, 7:1) and recrystallisation (MeCN/ Et_2O) gave the title compound as a pale yellow solid (145 mg, 8 %); δ_{H} (300 MHz, D_2O) 3.46-3.52 (2H, m, H-2, H-3), 3.56-3.62 (2H, m, H-4, H-5), 3.76 (1H, dd, $J_{5,6}$ 5.7 Hz, $J_{6,6'}$ 12.5 Hz, H-6), 3.93 (1H, dd, $J_{5,6'}$ 2.2 Hz, H-6'), 5.07 (1H, d, $J_{1,2}$ 9.6 Hz, H-1), 7.67 (2H, d, J 9.0 Hz, Ar-H), 8.22 (2H, d, J 9.0 Hz, Ar-H); HRMS (ESI) Cald. for $\text{C}_{12}\text{H}_{15}\text{NO}_7\text{SNa}^+$ ($M + \text{Na}^+$) 340.0461. Found 340.0458.




Scheme S1: Synthesis of aryl thioglycosides

1.6.2. Toluoyl 2,3,4,6-tetra-*O*-acetyl- β -D-thioglucopyranoside **2**




1,2,3,4,6-Penta-*O*-acetyl- β -D-glucopyranoside (3.0 g, 7.69 mmol) and toluoyl thiol (6.4 g, 51.5 mmol) were stirred in dry DCM (70 mL) and the reaction mixture was cooled to 0 °C. $\text{BF}_3 \cdot \text{OEt}_2$ (6.7 mL, 54.6 mmol) was added dropwise and the reaction mixture was allowed to warm to room temperature. After 24 h, the mixture was diluted with DCM, washed with 1 M aq. NaOH (20 mL), sat. aq. NaHCO_3 (50 mL), brine (50 mL), dried (Na_2SO_4), filtered and concentrated *in vacuo*. Recrystallisation (heptane/EtOAc, 2:1) gave toluoyl 2,3,4,6-tetra-*O*-acetyl- β -D-thioglucopyranoside **2** as a white crystalline solid (1.5 g, 43 %); δ_{H} (300 MHz, CDCl_3) 1.99, 2.01, 2.08, 2.09 (12H, 4 x s, 4 x CO_2CH_3), 2.35 (3H, s, Ar CH_3), 3.70 (1H, m, H-5), 4.19 (2H, m, H-6, H-6'), 4.63 (1H, d, $J_{1,2}$ 10 Hz, H-1), 4.93 (1H, at, J 10 Hz, H-2), 5.02 (1H, at, J 9.7 Hz, H-4), 5.21 (1H, at, J 9.3 Hz, H-3), 7.13 (2H, m, Ar-H), 7.39 (2H, m, Ar-H); HRMS (ESI) Cald. For $\text{C}_{21}\text{H}_{26}\text{O}_9\text{SNa}^+$ ($M + \text{Na}^+$) 477.1190. Found 477.1202.

1.6.3. Toluoyl β -D-thioglucopyranoside **3**




Toluoyl 2,3,4,6-tetra-*O*-acetyl- β -D-thioglucopyranoside **2** (1.0 g, 2.20 mmol) was stirred in dry MeOH (10 mL) and NaOMe (50 μ L of a 25 wt% solution in MeOH, 0.22 mmol) was added. The reaction was allowed to stir for 2 h, at which time, the mixture was neutralised using Dowex[®] 50WX8, filtered, and concentrated *in vacuo*. Trituration of the residue with Et₂O and filtration of the resulting solid gave toluoyl β -D-thioglucopyranoside **3** as a white powder (630 mg, 100 %); δ_{H} (300 MHz, CD₃OD) 2.31 (3H, s, ArCH₃), 3.17 (1H, dd, $J_{2,3}$ 8.3 Hz, $J_{1,2}$ 9.7 Hz, H-2), 3.25-3.39 (3H, m, H-3, H-4, H-5), 3.65 (1H, m, H-6), 3.86 (1H, dd, $J_{6,6'}$ 12.1 Hz, $J_{5,6}$ 1.8 Hz), 4.50 (1H, d, $J_{1,2}$ 9.7 Hz, H-1), 7.12 (2H, m, Ar-H), 7.46 (2H, m, Ar-H); HRMS (ESI) Calcd. for C₁₃H₁₇O₅S⁻ (M - H⁺) 285.0802. Found 285.0798.

1.6.4. Phenyl 2,3,4,6-tetra-*O*-acetyl- β -D-thioglucopyranoside **4**




Glucose pentaacetate (1.0 g, 2.56 mmol) and thiophenol (360 μ L, 3.59 mmol) were stirred in dry DCM (2 mL) and the mixture was cooled to 0 °C. BF₃.OEt₂ (920 μ L, 7.43 mmol) was added dropwise and the mixture was allowed to warm to room temperature. After 16 h, the mixture was diluted with DCM (50 mL), washed with NaOH (10 mL of a 1 M aq. solution), NaHCO₃ (20 mL of a saturated solution), brine (20 mL), dried (Na₂SO₄), filtered, and concentrated *in vacuo*. The product was recrystallised (heptane/EtOAc, 2:1) filtered, and allowed to air-dry to give the phenyl 2,3,4,6-tetra-*O*-acetyl- β -D-thioglucopyranoside **4** as a white crystalline solid (760 mg, 59 %); δ_{H} (300 MHz, CDCl₃) 1.99, 2.02, 2.08, 2.09 (12H, 4 x s, 4 x CH₃CO₂), 3.73 (1H, ddd, $J_{4,5}$ 10.1 Hz, $J_{5,6}$ 2.6 Hz, $J_{5,6'}$ 5.0 Hz, H-5), 4.15-4.26 (2H, m, H-6, H-6'), 4.71 (1H, d, $J_{1,2}$ 10.1 Hz, H-1), 4.99 (1H, at, J 9.4 Hz, H-2), 5.04 (1H, at, J 9.4 Hz, H-4), 5.23 (1H, at, J 9.7 Hz, H-3), 7.28-7.34 (3H, m, Ar-H), 7.48-7.51 (2H, m, Ar-H); HRMS (ESI) Calcd. for C₂₀H₂₄O₉SNa (M + Na⁺) 463.1033. Found 463.1022.

1.6.5. Phenyl thio-β-D-glucopyranoside 5




Phenyl 2,3,4,6-tetra-*O*-acetyl-1-thio-β-D-glucopyranoside **4** (500 mg, 1.14 mmol) was dissolved in anhydrous MeOH (5 mL) and stirred under N₂ atmosphere. NaOMe (25 μL of a 25 wt% solution in MeOH, 0.114 mmol) was then added. The reaction mixture was allowed to stir at rt until after 1 h, t.l.c (petrol:ethyl acetate, 1:1) indicated complete consumption of starting material (R_f 0.9) and formation of a single product (R_f 0). The reaction mixture was neutralized using Dowex® 50WX8 resin. The resin was filtered and the filtrate was concentrated to afford phenyl 1-thio-β-D-glucopyranoside **5** (310 mg, 100 %) as a white solid, δ_H (300 MHz, CD₃OD) 3.21 (1H, dd, *J*_{1,2} 9.7 Hz, *J*_{2,3} 8.5 Hz, H-2), 3.28-3.41 (3H, m, H-3, H-4, H-5), 3.67 (1H, dd, *J*_{6,6'} 12.2 Hz, *J*_{5,6} 5.3 Hz, H-6), 3.87 (1H, dd, *J*_{6,6'} 12.1 Hz, *J*_{5,6'} 1.8 Hz, H-6'), 4.60 (1H, d, *J*_{1,2} 9.7 Hz, H-1), 7.22-7.33 (3H, m, Ar-H), 7.54-7.58 (2H, m, Ar-H); HRMS (ESI) Calcd. For C₁₂H₁₆O₅S⁻ (M - H⁺) 271.0646. Found 271.0641.

1.6.6. 4-Bromophenyl 2,3,4,6-tetra-*O*-acetyl-β-D-thioglucopyranoside 6



Glucose pentaacetate (1.0 g, 2.56 mmol) and 4-bromothiophenol (681 mg, 3.59 mmol) were stirred in dry DCM (2 mL) and the mixture was cooled to 0 °C. BF₃·OEt₂ (920 μL, 7.43 mmol) was added dropwise and the mixture was allowed to warm to room temperature. After 16 h, the mixture was diluted with DCM (50 mL), washed with NaOH (10 mL of a 1 M aq. solution), NaHCO₃ (20 mL of a saturated solution), brine (20 mL), dried (Na₂SO₄), filtered, and concentrated *in vacuo*. The product was recrystallised (heptane/EtOAc, 2:1) and the solid was filtered and allowed to air-dry to give 4-bromophenyl 2,3,4,6-tetra-*O*-acetyl-β-D-thioglucopyranoside **6** as a white crystalline solid (580 mg, 44 %); δ_H (300 MHz, CDCl₃) 2.02, 2.04, 2.11, 2.11 (12H, 4 x s, 4 x CH₃CO₂), 3.74 (1H, ddd, *J*_{4,5} 10.0 Hz, *J*_{5,6} 4.6 Hz, *J*_{5,6'} 3.0 Hz, H-5), 4.16-4.27 (2H, m, H-6, H-6'), 4.68 (1H, d, *J*_{1,2} 10.0 Hz, H-1), 4.96 (1H, at, *J* 9.2 Hz, H-2), 5.04 (1H, at, *J* 9.8 Hz, H-4), 5.23 (1H, at, *J* 9.3 Hz, H-3), 7.28-7.39 (4H, m, Ar-H); HRMS (ESI) Calcd. for C₂₀H₂₃BrO₉SNa⁺ (M + Na⁺) 541.0138. Found 541.0135.



1.6.7. 4-Bromophenyl thio- β -D-glucopyranoside **7**





4-Bromophenyl 2,3,4,6-tetra-*O*-acetyl-1-thio- β -D-glucopyranoside **6** (500 mg, 0.96 mmol) was dissolved in anhydrous MeOH (5 mL) and stirred under N₂ atmosphere. NaOMe (21 μ L of a 25 wt% solution in MeOH, 0.11 mmol) was then added. The reaction mixture was stirred at rt until after 1 h, t.l.c (petrol:ethyl acetate, 1:1) indicated complete consumption of starting material (R_f 0.9) and formation of a single product (R_f 0). The reaction mixture was neutralized using Dowex[®] 50WX8 resin. The resin was filtered and the filtrate was concentrated to afford 4-bromophenyl 1-thio- β -D-glucopyranoside **7** (300 mg, 89 %) as a white solid; δ_{H} (300 MHz, CDCl₃) 3.16-3.38 (4H, m, H-2, H-3, H-4, H-5), 3.66 (1H, dd, $J_{6,6'}$ 12.1 Hz, $J_{5,6}$ 5.3 Hz, H-6), 3.87 (1H, dd, $J_{6,6'}$ 12.1 Hz, $J_{5,6'}$ 2.0 Hz, H-6'), 4.58 (1H, d, $J_{1,2}$ 9.7 Hz, H-1), 7.43-7.50 (4H, m, Ar-H); HRMS (ESI) Calcd. For C₁₂H₁₄O₅S⁻ (M - H⁺) 348.9751. Found 348.9745.

2. Spectral Data



2.1. *p*-Nitrophenyl β -D-glucopyranoside 1





2.2. Toluoyl 2,3,4,6-tetra-O-acetyl- β -D-thioglucopyranoside 2





2.3. Toluoyl β -D-thioglucoopyranoside 3





2.4. Phenyl 2,3,4,6-tetra-*O*-acetyl- β -D-thioglucopyranoside 4





2.5. Phenyl thio- β -D-glucopyranoside 5



2.6. 4-Bromophenyl 2,3,4,6-tetra-*O*-acetyl- β -D-thioglucopyranoside 6



2.7. 4-Bromophenyl thio- β -D-glucopyranoside 7



3. Supplementary references

1. N. Almulhim, N. R. Moody, F. Paradisi. *Appl. Microbiol. Biotechnol.*, 2020, **104**(10), 4407-4415.
2. M.R. Wilkins, E. Gasteiger, A. Bairoch, J.C. Sanchez, K.L. Williams, R.D. Appel, D.F. Hochstrasser, *Methods Mol Biol.*, 1999, **112**, 531-552.
3. Very simple K_M V_{max} toolkit. <http://www.ic50.tk/kmvmx.html> (Accessed 27.09.2022).
4. T. Tanaka, T. Matsumoto, M. Noguchi, A. Kobayashi, S. Shoda, *Chem. Lett.*, 2009, **38**(5), 458-459
5. N. Yoshida, M. Noguchi, T. Tanaka, T. Matsumoto, N. Aida, M. Ishihara, A. Kobayashi, S.I. Shoda. *Chem Asian J.*, 2011, **6**(7), 1876-1885.